Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy

iHealthScreen Inc · with National Institutes of Health (NIH) · NCT07151001

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 22+ · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
922
US sites recruiting
1
Study start
January 1, 2025
Record last updated
September 2, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

In this pivotal trial, we aim to perform a prospective study to find the efficacy of iPredict-DR, an artificial intelligence (AI) based software tool on early diagnosis of Diabetic Retinopathy (DR) in the primary care and endocrinology clinics. DR is one of the leading causes of blindness in the United States and other developed countries. Every individual with diabetes is at risk of DR. It does not show any symptoms until the disease is progressed to advanced stages. If the disease is caught at an early stage, it can be prevented, managed, or treated effectively. Currently, screening for DR is done by the Ophthalmologists, which is limited to areas with limited availability. This is also time-consuming and expensive. All of these can be complemented by automated screening and set up the screening in the primary care clinics.

Being studied: No intervention

Conditions: Diabetes; Diabetic Retinopathy

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age of Subjects: Patients ≥ 22 years of age.
  • Gender of Subjects: Both males and females will be invited to participate.
  • Subjects with diabetes (A1C level ≥ 6.5).
  • Subjects must be willing and are able to comply with clinic visit, understand the study-related procedures/provisions, and provide signed informed consent.

Exclusion Criteria

  • Unable to understand the study, Our unable to or unwilling to sign the informed consent
  • Previously diagnosed with macular edema, any form of diabetic retinopathy, radiation retinopathy, or retinal vein occlusion
  • participants who are experiencing persistent vision loss, blurred vision, or other vision problems that should be evaluated by an eye care provider
  • subjects whose retinal images were used in training, validating, or developing the device
  • Currently participating in another investigational eye study or actively receiving investigational product for DR or DME.
  • A condition that, in the opinion of the investigator, would preclude participation in the study;
  • Contraindicated for imaging by fundus imaging systems used in the study because of hypersensitivity to light, recently underwent photodynamic therapy, or was taking medication that causes photosensitivity.

Recruiting US locations

Study contacts (from the official record)

  • Alauddin Bhuiyan · 718-926-9000 · bhuiyan@ihealthscreen.org
  • Fariha Nuha, BS (Comp. Biology) · 718-912-0837 · fariha@ihealthscreen.org
All diabetes studies in New York →
Pivotal Trial of Automated Artificial Intelligence (AI) Based… (NCT07151001) | Bored Studies